

Applicants: Philip O. Livingston and Friedhelm Helling
Serial No.: 08/196,154
Filed : November 16, 1995
Page 2

applicants' right to pursue the subject matter of this claim in a later-filed application. Please also amend claim 113 under the provisions of 37 C.F.R. § 1.121(b) by deleting the bracketed material and inserting the underlined material as follows:

- 113. (Amended) A method of [preventing or] treating a cancer in a subject which comprises administering to the subject an effective cancer [preventing or] treating amount of a composition which comprises:
- Sub
G^a
F1
- a) a conjugate of i) a GM2 or GD2 ganglioside derivative which comprises an unaltered oligosaccharide part and an altered ceramide portion comprising a sphingosine base, to ii) Keyhole Limpet Hemocyanin or a derivative thereof comprising an e-aminolysyl group;
 - b) a saponin derivable from the bark of a Quillaja saponaria Molina tree; and
 - c) a pharmaceutically acceptable carrier;
- the relative amounts of such conjugate and such saponin being effective to stimulate or enhance antibody production in the subject, wherein in the conjugate the ganglioside derivative is conjugated to Keyhole Limpet Hemocyanin or the derivative thereof through a C-4 carbon of the sphingosine base of the ceramide portion of the ganglioside derivative to the e-aminolysyl group of Keyhole Limpet Hemocyanin or the derivative thereof, so as to thereby [prevent or] treat a cancer in the subject.--

REMARKS

Claims 97-118 are pending in the subject application. Applicants have hereinabove canceled claim 112 without disclaimer prejudice to